Inherited retinal diseases target of potential treatments

Article

Forty potential new treatments for inherited retinal diseases are under development, according to a review by the National Institute for Health Research (NIHR) Horizon Scanning Centre (HSC), working with charitable organization Fight for Sight.

Forty potential new treatments for inherited retinal diseases are under development, according to a review by the National Institute for Health Research (NIHR) Horizon Scanning Centre (HSC), working with charitable organization Fight for Sight.

The promising technologies - identified through consultations and focus groups with patients, families, caregivers and eye health professionals - include nine gene therapy approaches, ten medical devices, five drugs and five regenerative and cell development approaches. Eleven additional technologies are at a very early stage of development. Most of the technologies identified are in clinical trials or are expected to be soon.

"With further support and funding, these therapies and technologies could have a major impact on people's lives," says Michele Acton, chief executive of Fight for Sight.

For more information on the review visit the NIHR HSC website here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.